Benign prostatic hyperplasia: Natural evolution versus medical treatment

被引:0
|
作者
DaSilva, FC
机构
关键词
benign prostatic hyperplasia; alpha(1)-blockers; quality of life; epidemiology;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The epidemiology and natural evolution of benign prostatic hyperplasia (BPH) are important when considering the topic of natural evolution versus medical treatment, The incidence of BPH increases with age; it is thought that about 75 % of men over 50 years of age suffer from some symptoms commonly associated with BPH. There are also differences in the incidence of BPH between various racial and ethnic groups. For example, it is considerably less common amongst Japanese men compared with Caucasians. Evidence from prospective studies, retrospective studies and the placebo arms of randomised, controlled studies regarding the natural evolution of BPH suggests that a strategy of 'watchful waiting' may be considered as a treatment option as the majority of patients do not show a worsening of symptoms over time, However, the chance for improvement of symptoms and the degree of symptom improvement has been shown to be higher with alpha(1)-blocker therapy than with 'watchful waiting', as both symptoms and treatment have an impact on the patient's quality of life, there is now a strong case for involving the patient in making quality-of-life decisions based on his own preferences and attitudes.
引用
收藏
页码:34 / 37
页数:4
相关论文
共 50 条
  • [31] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Martinelli, E.
    UROLOGE, 2016, 55 (01): : 81 - 94
  • [32] Medical therapy for benign prostatic hyperplasia progression
    McVary K.T.
    Current Urology Reports, 2002, 3 (4) : 269 - 275
  • [33] Association of the Benign Prostatic Hyperplasia and erectile dysfunction, the current treatment modalities in Benign Prostatic Hyperplasia
    Sen, Volkan
    Demir, Omer
    Esen, Ahmet Adil
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (04): : 62 - 64
  • [34] Underdetection of clinical benign prostatic hyperplasia in a general medical practice
    McNaughton, MF
    Friedman, RH
    Ash, A
    Hall, R
    Moskowitz, MA
    JOURNAL OF GENERAL INTERNAL MEDICINE, 1996, 11 (09) : 513 - 518
  • [35] Benign prostatic hyperplasia medical treatment: Systematic review of the literature by the CTMH/AFU
    Robert, G.
    Descazeaud, A.
    Delongchamps, N. Barry
    Cornu, J-N
    Azzouzi, A. R.
    Haillot, O.
    Devonec, M.
    Fourmarier, M.
    Ballereau, C.
    Lukacs, B.
    Dumonceau, O.
    Saussine, C.
    de la Taille, A.
    PROGRES EN UROLOGIE, 2012, 22 (01): : 7 - 12
  • [36] Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options
    Liatsikos, Evangelos
    Kyriazis, Iason
    Kallidonis, Panagiotis
    Stolzenburg, Jens-Uwe
    AGING MALE, 2011, 14 (03) : 141 - 149
  • [37] Epidemiology of benign prostatic hyperplasia
    Robert, G.
    De La Taille, A.
    Descazeaud, A.
    PROGRES EN UROLOGIE, 2018, 28 (15): : 803 - 812
  • [38] BENIGN PROSTATIC HYPERPLASIA - SURGICAL VERSUS NONSURGICAL TREATMENT - A CRITICAL-REVIEW
    BOCCONGIBOD, L
    EUROPEAN UROLOGY, 1991, 20 : 59 - 62
  • [39] Safety profile of treatment with greenlight versus Thulium Laser for benign prostatic hyperplasia
    Campobasso, Davide
    Barbieri, Antonio
    Bocchialini, Tommaso
    Pozzoli, Gian Luigi
    Dinale, Francesco
    Facchini, Francesco
    Grande, Marco Serafino
    Kwe, Jean Emmanuel
    Larosa, Michelangelo
    Guarino, Giulio
    Mezzogori, Davide
    Simonetti, Elisa
    Ziglioli, Francesco
    Frattini, Antonio
    Maestroni, Umberto Vittorio
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2023, 95 (01)
  • [40] Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
    Yamaguchi, Kenya
    Aoki, Yutaka
    Yoshikawa, Tetsuo
    Hachiya, Takahiko
    Saito, Tadanori
    Takahashi, Satoru
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (12) : 1234 - 1238